PD-1, PD-L1, CTLA-4, OX-40, CD-40, GITR, 4-1BB, TIGIT, LAG3
Immune checkpoints represent a group of extracellular membrane-bound proteins expressed on immune effector cells (e.g. T/B cells, NK cells), either inhibiting or stimulating effector cell proliferation. They are involved in eliminating foreign pathogens while maintaining self-tolerance, playing a crucial role in immunomodulation. Nowadays, production of therapeutic antibodies designed to block or activate immune checkpoints has become a new powerful approach for the treatment of cancer and other diseases.
To meet the growing demand of drug discovery on immune checkpoint targets, GenScript ProBio has partnered with Promega to developed a suite of cell-based reporter bioassays with high specificity, sensitivity and reproducibility. The Promega bioassays are complied with ICH guidelines with outstanding performance in antibody screening, characterization, potency testing and stability studies.
Therapeutic antibody discovery services – High quality antibody development platform to generate antibody leads, targeting immune checkpoints.
Mechanism of action: anti-GITR, anti-4-1BB, anti-OX40 and anti-CD40 antibodies function to mimic the ligand.
Mechanism of action: anti-CTLA-4, anti-TIGIT, anti-PD1, anti-PDL1 and anti-LAG3 antibodies block CTLA-4, TIGIT,
PD1, PDL1 and MHC I/II respectively to activate the downstream production of reporter enzyme.
Our customer service representatives are available 24 hours a day, Monday through Friday, to assist you.